Literature DB >> 4075316

Cellular basis for the inefficacy of 5-FU in human colon carcinoma.

B Drewinko, L Y Yang.   

Abstract

Five established human colorectal carcinoma cell lines with distinct phenotypic properties were exposed to different concentrations of 5-FU for varying time intervals. Effects were measured by sequential cell counts and by inhibition of colony formation. Treatment for 1 hr with 1 microgram/ml barely decreased survival of all cell lines as measured by colony formation; at a concentration of 100 microgram/ml, survival was modestly reduced for all cell lines, and for concentrations of 1000 microgram/ml, survival was decreased by greater than 50%. Extending the length of the treatment interval markedly increased the degree of cell kill for all concentrations of 5-FU. Treatment for greater than 24 hrs resulted in almost complete extermination of colony-forming cells, even for relatively resistant cell lines. The effect of 5-FU treatment on cell number was more complex and depended on drug concentration, length of treatment, and type of cell line. In general, decrements in cell numbers were somewhat related to both drug concentration and length of treatment interval, especially if performed 7 days after terminating drug treatment. Earlier cell counts were inconclusive and the same result could be obtained for different drug concentrations or treatment intervals. Furthermore, these results would change on a daily basis. More important, cell count results never correlated with the survival endpoint measured by inhibition of colony formation. Our results suggest that enhancement of the currently poor performance of 5-FU in the treatment of human colon carcinoma could originate from changing the administration modality to long-term infusion.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4075316

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  16 in total

1.  Twenty-four hour intra-arterial infusion of 5-fluorouracil, cisplatin, and leucovorin is more effective than 6-hour infusion for advanced hepatocellular carcinoma.

Authors:  Hidenari Nagai; Masahiro Kanayama; Katsuya Higami; Kouichi Momiyama; Akiko Ikoma; Naoki Okano; Katsuhiko Matsumaru; Manabu Watanabe; Koji Ishii; Yasukiyo Sumino; Kazumasa Miki
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

2.  A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions.

Authors:  H Bailey; G Wilding; K D Tutsch; R Z Arzoomanian; D Alberti; M B Tombes; J L Grem; D R Spriggs
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

3.  Pyridoxine therapy for palmar-plantar erythrodysesthesia associated with continuous 5-fluorouracil infusion.

Authors:  C J Fabian; R Molina; M Slavik; S Dahlberg; S Giri; R Stephens
Journal:  Invest New Drugs       Date:  1990-02       Impact factor: 3.850

Review 4.  Continuous infusion of chemotherapy: focus on 5-fluorouracil and fluorodeoxyuridine.

Authors:  R L Poorter; P J Bakker; C H Veenhof
Journal:  Pharm World Sci       Date:  1998-04

5.  Concentration and time dependence of the toxicity of fluorinated pyrimidines to HT 29 colorectal carcinoma cells.

Authors:  K H Link; K R Aigner; K Peschau; M Warthona; K Schwemmle; P V Danenberg
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

6.  Inhibition of fluorouracil catabolism in cancer patients by the antiviral agent (E)-5-(2-bromovinyl)-2'-deoxyuridine.

Authors:  H J Keizer; E A De Bruijn; U R Tjaden; E De Clercq
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

Review 7.  The oral fluorinated pyrimidines.

Authors:  J S de Bono; C J Twelves
Journal:  Invest New Drugs       Date:  2001       Impact factor: 3.850

8.  Combination therapy of intra-arterial 5-fluorouracil and systemic pegylated interferon α-2b for advanced hepatocellular carcinoma.

Authors:  Kazuhiro Kasai; Akira Ushio; Yukiho Kasai; Kei Sawara; Yasuhiro Miyamoto; Kanta Oikawa; Hidekatsu Kuroda; Yasuhiro Takikawa; Kazuyuki Suzuki
Journal:  Int J Clin Oncol       Date:  2010-12-04       Impact factor: 3.402

9.  Pharmacokinetic properties and antitumor efficacy of the 5-fluorouracil loaded PEG-hydrogel.

Authors:  Hee Yi; Hee-Jung Cho; Soo-Min Cho; Dong-Goo Lee; A M Abd El-Aty; So-Jeong Yoon; Gun-Won Bae; Kwang Nho; Bokyung Kim; Chi-Ho Lee; Jin-Suk Kim; Michael G Bartlett; Ho-Chul Shin
Journal:  BMC Cancer       Date:  2010-05-18       Impact factor: 4.430

10.  Antitumor effect of intratumoral administration of fluorouracil/epinephrine injectable gel in C3H mice.

Authors:  N Y Yu; E K Orenberg; E E Luck; D M Brown
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.